Page 4 - Christopher Posner News Today

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The […]

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) CEO Christopher Posner sold 2,006 shares of Cara Therapeutics stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $12.67, for a total value of $25,416.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which […]

KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed Initiation of Oral...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Business Wire. The AP news staff was not involved in its creation.

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use recommends approval of Kapruvia® as first therapy in Europe for the treatment of chronic kidney... | February 28, 2022

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia(difelikefalin) as first therapy in Europe for the treatment of

25.02.2022 - Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus (CKD-aP) in hemodialysis patientsEuropean Commission ... Seite 1

18.02.2022 - Presentation to highlight oral difelikefalin Phase 3 pruritus programsSTAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) - Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to ...

Stamford-based Cara Therapeutics, which recently gained FDA approval for its first drug,...